Intrathecal Ketorolac in Patients With Intrathecal Morphine Dose Escalation
WithdrawnPhase 2NCT00349401
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The purpose of this study is to determine how the drug ketorolac, when given with the spinal morphine, affects pain.
Study details
- Official title
- Intrathecal Ketorolac in Patients With Intrathecal Morphine Dose Escalation
- Conditions
- Interventions
- Drug: ketorolac
- Drug: morphine
- Sponsor
- Wake Forest University Health Sciences
- Start date
- 2006-12
- Sex
- All
- Age range
- from 18 Years to 70 Years
- Results posted
- No results posted in this snapshot
- Total sites listed
- 0
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Implanted spinal pump for at last 9 months * Must be receiving and the dose must have been doubled in the past 6 months * Currently taking 60-200 mg morphine equivalent as oral rescue per day * Men and women, ages 18-70 * Weigh no more that 250 pounds * Neuropathic pain Exclusion Criteria: * Pregnancy * Unstable medical problems (heart lung, liver, kidney, or nervous system) * Allergy to morphine, ketorolac, or drugs which may be used to treat side effects
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00349401